Kiromic BioPharma, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial to evaluate KB-GDT-01, or Deltacel, in combination with an anti-tumor therapy for the treatment of non-small cell lung cancer (NSCLC). Deltacel is the Company's allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cell (GDT) therapy The Company is seeking to address the significant unmet need of applying cell therapy to treat solid malignancies, which comprise 90% of all cancers, including NSCLC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | +7.97% | +3.17% | +273.56% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+273.56% | 50.13L | |
+18.72% | 12TCr | |
+14.53% | 11TCr | |
-2.88% | 2.47TCr | |
+4.48% | 2.27TCr | |
-9.95% | 1.81TCr | |
-41.04% | 1.67TCr | |
-11.83% | 1.66TCr | |
+1.46% | 1.35TCr | |
+24.22% | 1.13TCr |
- Stock Market
- Equities
- KRBP Stock
- News Kiromic BioPharma, Inc.
- Kiromic Biopharma, Inc. Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer